Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Teva Pharmaceutical Industries Ltd (TEVA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart
Realtime quote and/or trade prices are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 12,994,640
  • Shares Outstanding, K 1,016,000
  • Annual Sales, $ 21,903 M
  • Annual Income, $ 329,000 K
  • 36-Month Beta 0.52
  • Price/Sales 0.58
  • Price/Cash Flow 1.91
  • Price/Book 0.48

Price Performance

See More
Period Period Low Period High Performance
1-Month
10.85 +27.56%
on 11/02/17
14.99 -7.67%
on 10/20/17
-0.90 (-6.11%)
since 10/17/17
3-Month
10.85 +27.56%
on 11/02/17
20.10 -31.14%
on 09/12/17
-3.26 (-19.06%)
since 08/17/17
52-Week
10.85 +27.56%
on 11/02/17
39.08 -64.59%
on 11/18/16
-25.05 (-64.41%)
since 11/17/16

Most Recent Stories

More News
Teva Announces Prescription Copay Savings Program for Generic Gleevec(R) Tablets in the United States

Teva Pharmaceuticals USA, a subsidiary of Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced the launch of a prescription copay assistance program in the U.S. for...

TEVA : 13.84 (+8.21%)
AstraZeneca's (AZN) Asthma Drug Benralizumab Approved by FDA

AstraZeneca (AZN) received FDA approval for benralizumab for treating severe eosinophilic asthma.

AZN : 33.46 (-0.18%)
TEVA : 13.84 (+8.21%)
AMGN : 170.00 (-0.45%)
GSK : 35.06 (-0.37%)
Orexigen (OREX) Q3 Loss Narrower Than Expected, Stock Up

Orexigen (OREX) reported a narrower-than-expected loss on higher Contrave volumes.

OREX : 1.69 (+4.32%)
SCMP : 10.55 (+1.93%)
TEVA : 13.84 (+8.21%)
MKGAF : 107.5000 (+1.19%)
Today's Research Reports on Trending Tickers: Teva Pharmaceutical and Transocean

NEW YORK, NY / ACCESSWIRE / November 14, 2017 / After posting its first weekly loss in two months on Friday, the Dow Jones and S&P 500 Index opened the week in the green on Monday. The Dow Jones Industrial...

RIG : 10.35 (+1.17%)
TEVA : 13.84 (+8.21%)
BioDelivery (BDSI) Q3 Earnings, Sales Beat Estimates

BioDelivery (BDSI) reports narrower-than-expected loss in Q3. Revenues also surpass estimates and increase significantly year over year.

LGND : 140.31 (-0.99%)
ENDP : 7.54 (+3.29%)
BDSI : 2.25 (unch)
TEVA : 13.84 (+8.21%)
VIVUS (VVUS) Q3 Loss Narrows, Qsymia Falters, Shares Down

VIVUS (VVUS) reported third-quarter results wherein it reported narrower-than- expected loss. However, Qsymia sales fell from the year-ago period.

VVUS : 0.67 (-1.47%)
RDY : 35.91 (+0.67%)
EXEL : 26.38 (+2.13%)
TEVA : 13.84 (+8.21%)
Drug Makers Stock Performance Review -- Amarin, Endo, Ionis Pharma, and Teva Pharma

If you want a Stock Review on AMRN, ENDP, IONS, or TEVA then come over to http://dailystocktracker.com/register/ and sign up for your free customized report. Pharmaceutical manufacturers compete to discover...

ENDP : 7.54 (+3.29%)
AMRN : 3.24 (-5.26%)
IONS : 54.15 (-0.39%)
TEVA : 13.84 (+8.21%)
Today's Research Reports on Stocks to Watch: Teva Pharmaceutical and TherapeuticsMD

NEW YORK, NY / ACCESSWIRE / November 7, 2017 / It was a good start to the week for Teva Pharmaceutical on Monday, as a Reuters report revealed that a British billionaire may be interested in a $3 billion...

TEVA : 13.84 (+8.21%)
TXMD : 5.85 (-0.85%)
Mylan (MYL) Misses on Earnings and Sales Estimates in Q3

Mylan (MYL) missed both earnings and sales estimates in the third quarter of 2017 as EpiPen sales continue to decline further.

MYL : 37.59 (+0.24%)
TEVA : 13.84 (+8.21%)
RHHBY : 29.1000 (+0.71%)
GSK : 35.06 (-0.37%)
Pharma Stock Roundup: Pfizer, Teva's Q3 Earnings, Novartis Seeks New Indication for Kymriah

It was all about earnings last week with companies like Pfizer (PFE), Teva and Allergan reporting third quarter results.

AZN : 33.46 (-0.18%)
MRK : 55.20 (+0.05%)
NVS : 83.98 (+1.16%)
TEVA : 13.84 (+8.21%)
VRX : 14.69 (+2.44%)
PFE : 35.37 (-0.53%)
BMY : 61.32 (-0.89%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More

Business Summary

TEVA Pharmaceuticals USA, the business is to develop, manufacture, and market generic pharmaceuticals. Teva USA sells its products to chains, wholesalers, distributors, hospitals, managed care entities, and government agencies. The company markets a variety of dosage forms, including both extended...

See More

Key Turning Points

2nd Resistance Point 14.75
1st Resistance Point 14.30
Last Price 13.84
1st Support Level 13.05
2nd Support Level 12.25

See More

52-Week High 39.08
Fibonacci 61.8% 28.30
Fibonacci 50% 24.97
Fibonacci 38.2% 21.63
Last Price 13.84
52-Week Low 10.85

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart